as given in Table 4. (50%). Conclusion: Median survival rate was shorter in patients with one of the abnormalities including chromosome 13 aberrations, IGH rearrangements or P53 deletions. Chromosome 15 aberrations were significantly higher in patients with stage III disease (p=0.02). We conclude that FISH studies should be performed in conjunction with conventional cytogenetic analysis for prognosis in multiple myeloma patients. strong class=”kwd-title” Keywords: Cytogenetcis, Myeloma, FISH, Chromosomal aberrations Abstract Ama?: Multipl Myelom (MM) plazma hcrelerinin kemik ili?inde birikmesi, proliferasyonu ve monoklonal immunglobulin sekresyonu ile karakterize klonal bir hastal?kt?r. ?al??mam?zda Trk MM hastalar?nda kromozomal anomali s?kl???n?n interfaz FISH ve klasik kromozom analizi ile belirlenmesi, saptanan yeniden dzenlenmelerle hastal???n evresi ve prognozu aras?ndaki ili?kinin ara?t?r?lmas? ama?lanm??t?r. Gere? ve Y?ntemler: Multipl myelom tan?s? alan toplam 50 olgu klasik sitogenetik ve molekler sitogenetik (FISH) analizleri ile de?erlendirilmi?tir. FISH analizi ile; 13q14, 13q32, 17p13 b?lgelerindeki delesyonlar, IGH b?lgesini i?eren yeniden dzenlenmeler ve 5, 9, 15. kromozomlar?n monozomi ve/veya trizomileri incelenmi?tir. Bulgular: Konvansiyonel sitogenetik analiz olgular?n 32 tanesinde ger?ekle?tirilebilmi? olup 27 olguda (%84.3) Hexachlorophene normal karyotip izlenirken 5 olguda (%15.6) kromozom aberasyonlar? g?zlenmi?tir. FISH analizinde; olgular?n %18 inde (9/50) de?erlendirilen tm parametreler i?in normal sonu? bulunmu?tur. Olgular?n %82 sinde ise (41/50) FISH analizi ile en az bir anomali g?zlenmi?tir. Olgular?n %54nde (27/50) kromozom 13 aberasyonlar? g?zlenmi?tir. ?kinci en s?k g?zlenen aberasyon % 50 oran?yla kromozom 15 aberasyonlar?d?r. Sonu?: ?al??mam?zda 13. kromozom aberasyonlar?, IGH translokasyonlar? ve P53 delesyonlar?ndan en az birini bulunduran olgular?n ortalama median sa? kal?m srelerinin di?erlerinden daha k?sa oldu?u g?rlm?tr. Kromozom 15 aberasyonlar? evre 3 ile ili?kili oldu?u g?rlm?tr (P=0.02). ?al??mam?zda elde etti?imiz verilere g?re MM l? olgularda konvansiyonel sitogenetik ve ?zellikle FISH y?nteminin hastal???n takip ve prognozunda birlikte kullan?lmas?n?n ?nemli oldu?unu d?nmekteyiz. INTRODUCTION Multiple myeloma (MM) is a common hematologic malignancy characterized by abnormal production of monoclonal immunoglobulin (IgG, IgA, IgM) or Bence Jones protein (free monoclonal k or light chains). Genetic changes have been implicated in the accumulation and uncontrolled proliferation of malignant plasma cells (PC) within the bone marrow. Among different prognostic elements in MM, cytogenetic abnormalities (CA) recognized by regular cytogenetics (CC) and Seafood studies have surfaced as a significant 3rd party parameter predicting the Hexachlorophene medical result [1,2,3,4,5,6]. The most important structural chromosomal adjustments are chromosome 1 structural aberrations, chromosome 13 abnormalities, translocations concerning immunoglobulin Rabbit polyclonal to VCAM1 heavy string locus (IGH) of chromosome 14, trisomies and P53 gene deletions [1,2,5,6,7,8,9,10,11]. In comparison to lymphomas and leukemias, cytogenetic changes aren’t quality in MM. CA in MM individuals are connected with karyotypic difficulty, length and stage of disease and response to therapy [9]. The hypoproliferative character of clonal Personal computers account for the fantastic problems in obtaining cytogenetic data [2,3,6,9,10,11,12,13]. Irregular karyotypes have already been reported in 30-50% of individuals. Karyotypes are complicated and aneuploidy can be noticed Hexachlorophene [3 generally,5,6,9,14,15]. In today’s study, we looked into the rate of recurrence of CA in Turkish individuals with MM, using interphase CC and FISH. We also examined their romantic relationship between Hexachlorophene medical and lab features and analyzed their effect on general survival. Strategies and Components 50 individuals who was simply identified as having MM were enrolled. Bone tissue marrow (BM) examples of individuals from two different Hematology Centers; from Sept 2005 to January 2008 were described our Cancer Cytogenetics Portion of the Medical Genetics Department. The consent forms.